<DOC>
	<DOCNO>NCT01183117</DOCNO>
	<brief_summary>The main objective evaluate safety efficacy SM-01 stenting ( Cordis S.M.A.R.T.â„¢ Nitinol Stent System ) treatment SFA lesion compare PTA ( balloon angioplasty ) . If SM-01 use PTA-bailout patient , case assess separately .</brief_summary>
	<brief_title>A Clinical Investigation SM-01 Stenting Versus PTA Treatment Superficial Femoral Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1 . Age &gt; = 20 year . 2 . Symptomatic leg ischemia Rutherford Classification ( category1 , 2 , 3 ) . 3 . Lesion length &gt; = 40 mm &lt; = 150 mm . ( must treatable two SM01 stent . Overlap 1cm two stent use ) 4 . Reference vessel diameter ( RVD ) &gt; = 4.0 mm &lt; = 7.0 mm . 5 . All lesion locate &gt; = 3.0 cm proximal superior edge patella , &gt; = 1.0 cm distal SFA / PFA bifurcation . 6 . &gt; = 50 % stenosis total occlusion . 7 . Patent infrapopliteal popliteal artery , i.e. , singlevessel runoff good least one three vessel patent ( &lt; 50 % stenosis ) ankle foot . 8 . Patient legally authorize representative must provide write informed consent prior initiation study procedure . 9 . A patient bilateral obstructive SFA disease eligible enrollment study . If patient bilateral disease enrol , target limb severe limb . The severe limb select accord clinical symptomatology . If clinical symptomatology similar , clinically severe lesion select . The contralateral procedure do least 30 day index procedure severe limb attempt . 1 . Recent hemorrhagic disease within past 3 month . 2 . Aneurysm SFA popliteal artery . 3 . Acute limb occlusion . 4 . Procedures predetermine require stentinstent placement obtain patency , severe calcification resistant stenting , instent restenosis . 5 . Poor iliac common femoral `` inflow '' . ( However , intervention restore adequate blood flow prior treatment study lesion allow . ) 6 . Known allergy aspirin , heparin , ticlopidine , bleed diathesis . 7 . Patients unable unwilling tolerate anticoagulant antiplatelet therapy . 8 . Patients unable unwilling tolerate contrast agent use intravascular procedure . 9 . Allergic nitinol tantalum . 10 . Women pregnant lactating , child bear potential , desire parent study period . 11 . Significant vessel tortuosity parameter prohibit access lesion would prevent delivery stent device . 12 . Revascularization involve limb 30 day prior index procedure plan revascularization within 30 day index procedure . 13 . Previously implant stent ( ) site artery treat . 14 . Requiring stent placement distal SFA popliteal artery . 15 . Presence femoral artificial graft . 16 . History participate clinical study within 1 year . 17 . Life expectancy le 3 year , factor prevent clinical followup . 18 . Receiving dialysis immunosuppressant therapy 19 . Serum creatinine level &gt; = 2.0 mg/dL procedure . 20 . A principal investigator coprincipal investigator determines patient unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>